XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2022
Significant Accounting Policies [Abstract]  
Inventory

Our inventory consisted of the following (in thousands):

 
September 30, 2022
   
December 31, 2021
 
Raw materials:
           
Raw materials- clinical
 
$
15,598
   
$
14,507
 
Raw materials- commercial
   
1,019
     
4,139
 
Total raw materials
   
16,617
     
18,646
 
Work in process
   
3,740
     
5,770
 
Finished goods
   
288
     
390
 
Total inventory
 
$
20,645
   
$
24,806
 
Weighted-Average Assumptions for Stock Options

Employee Stock Options:
 
Nine Months Ended
September 30,
 
   
2022
   
2021
 
Risk-free interest rate
   
1.9
%
   
0.5
%
Dividend yield
   
0.0
%
   
0.0
%
Volatility
   
54.9
%
   
54.3
%
Expected life*
 
6.3 years
   
4.9 years
 

*
In 2021, our Compensation Committee approved an amendment to the 2011 Equity Incentive Plan, or 2011 Plan, and 2020 Plan, that increased the contractual term of stock options granted under these plans from seven years to ten years for stock options granted on January 1, 2022 and thereafter. We determined that we are unable to rely on our historical exercise data as a basis for estimating the expected life of stock options granted to employees following this change because the contractual term changed and we have no other means to reasonably estimate future exercise behavior. We therefore used the simplified method for determining the expected life of stock options granted to employees in the nine months ended September 30, 2022. Under the simplified method, we calculate the expected term as the average of the time-to-vesting and the contractual life of the options. As we gain additional historical information, we will transition to calculating our expected term based on our historical exercise patterns.


Ionis Board of Director Stock Options:
 
Nine Months Ended
September 30,
 
   
2022
   
2021
 
Risk-free interest rate
   
2.9
%
   
1.2
%
Dividend yield
   
0.0
%
   
0.0
%
Volatility
   
56.2
%
   
55.9
%
Expected life
 
7.4 years
   
7.3 years
 
Weighted-Average Assumptions for ESPP

ESPP:
 
Nine Months Ended
September 30,
 
   
2022
   
2021
 
Risk-free interest rate
   
1.2
%
   
0.1
%
Dividend yield
   
0.0
%
   
0.0
%
Volatility
   
50.1
%
   
42.4
%
Expected life
 
6 months
   
6 months
 
Stock-Based Compensation Expense

The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2022 and 2021 (in thousands).

 
Three Months Ended
September 30,
   
Nine Months Ended
September 30,
 
 
2022
   
2021
   
2022
   
2021
 
Cost of sales
 
$
163
   
$
111
   
$
376
   
$
293
 
Research, development and patent expense
   
17,733
     
23,332
     
55,315
     
71,979
 
Selling, general and administrative expense
   
5,941
     
7,094
     
18,884
     
26,147
 
Total stock-based compensation expense
 
$
23,837
   
$
30,537
   
$
74,575
   
$
98,419